$CTSO

Sobel Alan D. purchased $15K of CTSO

Sobel Alan D. purchased 2,500 shares of Cytosorbents Corp (CTSO) at an average of $6.10 ($6.01–$6.12) across 3 trades on 2026-09-15.

Original reporting
SEC EDGAR · Sobel Alan D.
Published Sep 16, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CTSO
Neutral
low confidence
Mentioned
$CTSO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CTSONeutralLow
01

Why it matters

The director's purchase modestly raises his ownership, but the size is too small to indicate a material shift.

02

Market read

Routine insider buy with limited trading relevance; may be of interest to micro‑cap traders monitoring insider activity.

03

What to watch

If the director has access to upcoming product approvals, the buy might pre‑empt a catalyst not yet public.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑15

Background

Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$CTSONeutralLow confidence
Context

Director Alan D. Sobel purchased 2,500 shares of Cytosorbents for $15,254, increasing his stake to 9,887 shares.

Expected impact

Minimal upward pressure, unlikely to move the stock materially.

Evidence & confidence

The transaction size is modest relative to market cap and represents a routine 10b5‑1‑free purchase by a director.

Market effects

No significant sector impact; Cytosorbents operates in a niche biotech filtration market.

Limited to U.S. small‑cap investors.

Negligible.

Counterpoint

The purchase could be a signal of confidence despite the small amount, suggesting potential upside.

Key entities

  • Cytosorbents Corp

    US‑listed biotech company (ticker CTSO) focused on blood purification technologies.

  • Alan D. Sobel

    Director of Cytosorbents who executed the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CTSOMed

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.

$CTSOMed

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of…

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatme

$CTSOMedAI 9/10

Cytosorbents (CTSO) Q1 2026 Earnings Transcript

Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.